Targeting programmed death 1 (PD-1) or its ligand (PD-L1) offers significant clinical benefits in many cancers. One emerging biomarker of response to anti–PD-1/PD-L1 therapy is the tumor mutational burden,
1,2 which quantifies the number of somatic mutations in the tumor. The mutational burden has recently been shown by Yarchoan et al
3 to strongly correlate with the response rate for anti–PD-1/PD-L1 therapies across multiple cancer types. However, tumors containing comparably high mutational burden may exhibit variable responses,
4-6 suggesting that additional factors may contribute to anti–PD-1/PD-L1 response. Herein we systematically study this hypothesis, aiming to identify the most important additional factor(s) that contribute to response prediction. To this end we analyze whole-exome sequencing and RNA sequencing data of pretreated samples from 21 different cancer types in the Cancer Genome Atlas (TCGA). We find that a trivariate model composed of tumor mutational burden, estimated CD8
+ T-cell abundance (eCD8T), and fraction of high PD-1 messenger RNA expression samples (fPD1) markedly enhances the prediction of the response to anti–PD-1/PD-L1 therapy across different cancer types.